Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167990 | 0.83 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1C1PTGS1HTR1A | |
| SCHEMBL4488102 | 0.81 | AKR1C3 (0.44) | AKR1C3AKR1C2AKR1C1PTGS1HTR1A | |
| SCHEMBL2646897 | 0.79 | FFAR1 (0.36) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL1574429 | 0.79 | AKR1C3 (0.58) | AKR1C3AKR1C2AKR1C1PTGS1HTR1A | |
| SCHEMBL1624921 | 0.78 | SLC6A4 (0.52) | AKR1C3AKR1C2AKR1C1PTGS1HTR1A | |
| SCHEMBL23193690 | 0.78 | PTGS2 (0.42) | AKR1C3AKR1C2AKR1C1PTGS1GAA | |
| SCHEMBL2658173 | 0.76 | GCK (0.38) | — | |
| SCHEMBL22095156 | 0.75 | AKR1C3 (0.73) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL1587133 | 0.75 | AKR1C3 (0.73) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL11157705 | 0.74 | MEN1 (0.54) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | AKR1C3 921/4885AKR1C2 590/4885AKR1C1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.